Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;329:1345 (4 December), doi:10.1136/bmj.329.7478.1345
| The first 150 words of the full text of this article appear below. |
EDITOREditor's choice in the issue of 23 October on transparency and trust seems to perpetuate a misleading press citation of my testimony to a House of Commons Select Committee last month.1 The original statement, supported by the transcript, was that 50% of the articles dealing with therapeutics were ghost written, not 50% of all articles.2 3
I, like most readers, almost instinctively shrink from a claim that anything like 50% of the articles, even those on therapeutics alone, are ghost written in journals such as the BMJ, New England Journal of Medicine, JAMA, and the Lancet. But equally instinctively, most readers if asked to estimate how many of the key articles on their drugs, and this means articles in major journals, pharmaceutical companies are likely to have had a determining role in writing, would probably come up with figures close to 100%. If the question is in
David T Healy, professor of psychiatry
Bangor LL57 2PW Healy-Hergest@compuserve.com